Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.

[1]  H. Klingler,et al.  Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer. , 2012, Urology.

[2]  J. Fischer,et al.  High insulin‐like growth factor mRNA‐binding protein 3 (IMP3) protein expression is associated with poor survival in muscle‐invasive bladder cancer , 2012, BJU international.

[3]  S. Ergün,et al.  Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer , 2012, International journal of cancer.

[4]  G. Camussi,et al.  Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells , 2011, Leukemia.

[5]  B. Vanhaesebroeck,et al.  Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148 , 2011, Molecular biology of the cell.

[6]  J. Couchman,et al.  Transmembrane signaling proteoglycans. , 2010, Annual review of cell and developmental biology.

[7]  Mitsutoshi Nakamura,et al.  Role of syndecan‐1 (CD138) in cell survival of human urothelial carcinoma , 2010, Cancer science.

[8]  I. Kovalszky,et al.  Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer , 2009, Pathology & Oncology Research.

[9]  Viktoriya D. Nikolova,et al.  Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. , 2009, Carcinogenesis.

[10]  J. Couchman,et al.  A Conserved NXIP Motif Is Required for Cell Adhesion Properties of the Syndecan-4 Ectodomain* , 2006, Journal of Biological Chemistry.

[11]  I. Kovalszky,et al.  Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. , 2006, Oral oncology.

[12]  J. Stein,et al.  Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure , 2006, World Journal of Urology.

[13]  T. Ørntoft,et al.  Gene expression profiling of noninvasive primary urothelial tumours using microarrays , 2005, British Journal of Cancer.

[14]  Y. Hiramatsu,et al.  Prognostic significance of syndecan-1 expression in human endometrial cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[16]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[17]  E. Dahl,et al.  Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. , 2004, European journal of cancer.

[18]  A. Friedl,et al.  Induction of Syndecan-1 Expression in Stromal Fibroblasts Promotes Proliferation of Human Breast Cancer Cells , 2004, Cancer Research.

[19]  A. Rapraeger,et al.  Syndecans in tumor cell adhesion and signaling , 2004, Reproductive biology and endocrinology : RB&E.

[20]  T. Yoshizaki,et al.  Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration* , 2003, Journal of Biological Chemistry.

[21]  William C. Parks,et al.  Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury , 2002, Cell.

[22]  Heikki Joensuu,et al.  Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. , 2002, Cancer research.

[23]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[25]  Gillian Murphy,et al.  Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase , 2000, The Journal of cell biology.

[26]  A. Waage,et al.  Serum syndecan-1: a new independent prognostic marker in multiple myeloma. , 2000, Blood.

[27]  P. Heikkilä,et al.  Syndecan-1 expression has prognostic significance in head and neck carcinoma , 1999, British Journal of Cancer.

[28]  B. Weyn,et al.  Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.

[29]  Y. Kohgo,et al.  Reduced expression of syndecan‐1 in human hepatocellular carcinoma with high metastatic potential , 1997 .

[30]  K. Nackaerts,et al.  Heparan sulfate proteoglycan expression in human lung‐cancer cells , 1997, International journal of cancer.

[31]  Masato Kato,et al.  Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. , 1995, Molecular biology of the cell.

[32]  J. Heino,et al.  Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. , 1992, The Journal of biological chemistry.

[33]  D. Hanahan,et al.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.

[34]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[35]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .